x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012322
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro400 of human MTX1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MTX1 |
| UniProt No. | Q13505 |
| Gene ID | 4580 |
| Gene Description | Metaxin-1 and Metaxin-2 are part of the sorting and assembly machinery that has been associated with import of β-barrel proteins through the mitochondrial outer membrane. MTX1 and MTX2 can also function in mitochondrial trafficking in neurons. Studies of cells with a loss of MTX1 have shown that MTX1 is required for some forms of cell death, including TNF-α-induced cell death. Subsequent studies found that MTX1 and MTX2 can regulate TNF-α mediated apoptosis through association with the apoptotic effector protein Bak, and that phosphorylation of MTX1 controls Bak activation. MTX1 has also been shown to be targeted for basal piecemeal mitophagy in an LC3C- and p62/SQSMT1-dependent manner. MTX1 was identified as a regulator of sorafenib resistance in hepatocellular carcinoma by augmenting autophagy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
